Home Page >
News and press releases >
News archive >
OV05 Trial Results presented at ASCO May 2009
OV05 Trial Results presented at ASCO May
2009
OV05 A randomised trial in
relapsed ovarian cancer: early treatment based on CA125 levels
alone vs delayed treatment based on conventional clinical
indicators
First results of the MRC OV05/EORTC 55955
randomised trial were presented by Gordon Rustin at the plenary
session at the American Society of Clinical Oncology (ASCO) 2009
Annual Meeting in June. Results have subsequently be presented at
the presidential session of the joint European Cancer Organisation
(ECCO) and European Society of Medical Oncologists (ESMO) meeting
by Maria van der Burg, and by Gordon Rustin at the European Society
for Gynaecological Oncology (ESGO) and National Cancer Research
Institute (NCRI) meetings.
The first patient was registered in May
1996. These results show no evidence of a benefit from
starting chemotherapy for relapsed ovarian cancer earlier (based on
doubling of the blood marker CA125) compared to starting
chemotherapy when signs or symptoms of tumour recurrence develop.
The peer review publication will follow later in 2009
Summary in Plain
English (word doc)
ASCO slides
(powerpoint)
Last Update Date : 2/3/2010
